Females at reproductive age must have a negative urine pregnancy test prior to entry to this study
Female subjects must either be of non-reproductive potential, not breast-feeding or must have a negative urine or serum pregnancy test within  days of study treatment, confirmed prior to treatment on day .
Pregnancy (assessed by urine HCG)
Pregnant or lactating (female participant of childbearing potential must have negative serum or urine pregnancy test required within  days prior to start of treatment)
Female patients who are pregnant or of reproductive potential not willing to use an effective method of birth control during study treatment and for at least  months thereafter; serum or urine pregnancy test must be performed within  days of enrollment
DONOR: A serum or urine pregnancy test for females of reproductive potential must be conducted within  days prior to initiation of apheresis
Negative urine or serum pregnancy test in females. Male and female patients with reproductive potential must use an approved contraceptive method if appropriate
DONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within  days prior to enrollment (if female)
Negative serum or urine pregnancy test for women with reproductive potential
Pregnant or lactating women; female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within  hours before infusion
Pregnant or lactating women; female study participants of reproductive potential must have a negative serum pregnancy test at enrollment
Pregnancy (assessed by urine HCG)
Female patients who are at least -years-old or are post-menarchal must have a negative serum or urine pregnancy test prior to enrollment
DONOR: Pregnant females\r\n* NOTE: a serum or urine pregnancy test for females of reproductive potential must be conducted within  days prior to initiation of recipients conditioning regimen
Female patients with reproductive potential who do not have a negative blood or urine pregnancy test at screening
Pregnant or nursing (lactating) women, female study participants of reproductive potential must have a negative serum or urine pregnancy test within  hours before infusion
Pregnant or lactating women; female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within  hours before infusion
Women of reproductive potential must have negative urine pregnancy test
Women who are pregnant or lactating; all female patients with reproductive potential must have a negative pregnancy test prior to day 
DONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within  days prior to enrollment (if female)
Pregnancy or breastfeeding, or intention of becoming pregnant during the study. Female subjects must either be of non-reproductive potential or have a negative serum pregnancy test result within  days prior to initiation of study treatment
A negative serum pregnancy test, if female of reproductive potential
Female patients with reproductive potential who do not have a negative blood or urine pregnancy test at Screening or who are lactating.
Female subjects with reproductive potential must have a negative serum pregnancy test within  days prior to the start of therapy and on the first day of study drug administration.
Pregnant or nursing (lactating) women. NOTE: female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within  hours before infusion
Pregnant or lactating patients. Patients of childbearing potential must have a negative pregnancy test (urine or serum) within  days prior to registration and must implement adequate contraceptive measures during study treatment;
Female patients with reproductive potential who do not have a negative blood or urine pregnancy test at Screening.
Pregnant or lactating females; serum pregnancy test to be assessed within  days prior to study treatment start, or within  days (with a confirmatory urine pregnancy test within  days prior to study treatment start)
Women of reproductive potential must have a negative serum pregnancy test obtained within  days before the start of anetumab ravtansine
Pregnant or lactating women; female study participants of reproductive potential must have a negative serum pregnancy test at enrollment; a urine or serum pregnancy test will be performed within  hours before the RNA CART infusion
Pregnant or breastfeeding women; female study participants of reproductive potential must have a negative urine pregnancy test of enrollment; a serum pregnancy test will be performed within  weeks before infusion
Women of reproductive potential must not be pregnant or breastfeeding and have a negative urine or serum pregnancy test obtained within  days prior to the first dose of study treatment.
For female subjects with reproductive potential: a negative serum pregnancy test
Women must not be pregnant or lactating; women of reproductive-potential must have negative serum or urine pregnancy test within  days prior to study enrollment and agree to use an effective method to avoid pregnancy during and for  days following last cessation drug dose
Female participant who is post-menarchal must have a negative urine or serum pregnancy test
Negative serum pregnancy test within  days prior to enrollment in female subjects with reproductive potential
Pregnant or lactating women; the safety of this therapy on unborn children is not known; female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within  hours before infusion
Female research participants >=  years of age or post-menarchal must not be pregnant (confirmed by serum or urine pregnancy test within  week of study enrollment) or breastfeeding
Known pregnancy (negative serum or urine pregnancy test to be conducted within  days prior to enrollment) (Female only)
DONOR: Known pregnancy (negative serum or urine pregnancy test to be conducted within  days prior to enrollment) (Female only)
The patient is pregnant (confirmed by urine or serum pregnancy test) or lactating
Negative pregnancy test (if female in reproductive years)
Negative pregnancy test (if female in reproductive years)
Pregnant or lactating (female participant of childbearing potential must have negative serum or urine pregnancy test required within  days prior to start of treatment); male or female of reproductive potential has agreed to use effective contraception method for duration of study treatment
Subjects with reproductive potential must have a negative pregnancy test within  days before randomization
Female subjects who are of non-reproductive potential (Female subjects of reproductive potential must have a negative serum pregnancy test upon study entry).
Women of reproductive potential must have negative urine pregnancy test
Post-menarchal female has had negative serum pregnancy test within  days prior to enrollment
INCLUSION CRITERIA - HPC-A CELL DONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within  days prior to enrollment (if female)
(Female only) negative serum or urine pregnancy test (to be conducted within  days prior to enrollment)
(Female only) is not pregnant (negative serum or urine pregnancy test to be conducted within  days prior to admission for transplant)
DONOR: (Female only) is not pregnant (negative serum or urine pregnancy test to be conducted within  days prior to enrollment)
Pregnant or lactating (female participant of childbearing potential must have negative serum or urine pregnancy test required within  days prior to start of treatment)
Pregnant or lactating (female participant of childbearing potential must have negative serum or urine pregnancy test required within  days prior to start of treatment)
DONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within  days prior to enrollment (if female)
Patient is pregnant as confirmed by positive serum or urine pregnancy test within  days prior to enrollment
Not pregnant as confirmed by negative serum or urine pregnancy test within  days prior to enrollment (if female)
DONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within  days prior to enrollment (if female)
Females with reproductive potential: Must have a negative serum or urine pregnancy test within  days prior to the first dose of any study drug.
Patients who have a negative urine pregnancy test prior to enrollment; this should be done as part of pre-admission testing prior to surgery (within  days of study enrollment)
Women who are pregnant at time of enrollment; pregnancy will be assessed at enrollment using urine pregnancy test
Pregnancy: All female patients <  years old (yo) will be administered a urine pregnancy test prior to enrollment
Female participant of childbearing age must not be pregnant (confirmed by serum or urine pregnancy test within  week of eligibility) or lactating
(Female only) Known pregnancy (negative serum or urine pregnancy test to be conducted within  days prior to enrollment)
Pregnancy (assessed by urine HCG)
Pregnancy (urine hCG)
The patient is pregnant as confirmed by urine or serum pregnancy testing,
Pregnant or lactating women: pregnant women are excluded from this study because the effects of [F] FAZA in pregnancy are not known. A urine or serum pregnancy test will be performed before accrual after informed consent is obtained.
Women of reproductive potential must have a urine pregnancy test day of injection
Women of reproductive potential should have a negative serum or urine pregnancy test within one week prior to radiation planning CT scan
Female subjects with reproductive potential must have negative serum or urine pregnancy test
Pregnant women. Women of reproductive potential must have a negative serum or urine pregnancy test performed within  day
